Ketcher 08151615302D 1 1.00000 0.00000 0 15 15 0 1 0 999 V2000 11.9071 -10.2398 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 12.7558 -9.7406 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 11.0584 -9.6407 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 11.5577 -11.1884 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 13.6046 -10.2398 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 10.2596 -10.2398 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 11.0584 -8.6422 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 10.5592 -11.1884 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 14.4533 -9.7406 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 13.6046 -11.2383 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 9.9689 -11.9937 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 8.9669 -11.8843 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 8.3733 -12.6942 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 12.7558 -8.7421 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 13.6205 -8.2428 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 1 2 1 0 0 0 1 3 1 0 0 0 1 4 1 0 0 0 2 5 1 0 0 0 3 6 1 0 0 0 3 7 2 0 0 0 4 8 1 0 0 0 5 9 1 0 0 0 5 10 2 0 0 0 6 8 1 0 0 0 8 11 1 6 0 0 11 12 1 0 0 0 12 13 1 0 0 0 2 14 1 1 0 0 14 15 1 0 0 0 M END > CHEBI:133013 > brivaracetam > A non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy. > 3 > UCB34714; UCB 34714; 2-(2-Oxo-4-propylpyrrolidin-1-yl)butanamide > (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide > brivaracetam > Briviact > C11H20N2O2 > 212.289 > 212.15248 > 0 > N1([C@H](C(N)=O)CC)C(C[C@H](C1)CCC)=O > InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1 > MSYKRHVOOPPJKU-BDAKNGLRSA-N > 357336-20-0 > 9629290 > 357336-20-0 > D08879 > Brivaracetam > 26515103; 26664121; 26666500; 26719676; 26740317; 26760311; 26891946; 26899665; 26920914; 26944275; 27002062; 27146213; 27192732; 27217762; 27221208; 27236448; 27252986; 27265725; 27274002; 27335114; 27346728; 27389600; 27403785; 27450143; 27503181 $$$$